AZD8055: Technical Guidance for mTOR Pathway Research

What This Product Solves

AZD8055 (SKU A8214) is a highly selective ATP-competitive mTOR kinase inhibitor, designed for rigorous dissection of mTORC1 and mTORC2 signaling in cellular and animal models. The compound's specificity makes it a critical tool for researchers investigating the PI3K/Akt/mTOR signaling cascade, particularly in the context of cancer cell proliferation and metabolic regulation. Unlike less selective agents, AZD8055 enables targeted inhibition of both mTOR complexes with minimal off-target kinase activity, supporting mechanistic studies of growth, survival, and metabolic adaptation in preclinical settings.

This compound should be reserved for experimental workflows where precise control of mTOR pathway inhibition is necessary and where translational or clinical efficacy is not the primary endpoint. Its application is well-documented in cell-based and animal models, including studies on proliferation markers, glucose metabolism, and combinatorial inhibitor regimens. For further background, see the internal article "AZD8055: Technical Guidance for mTOR Pathway Inhibition", which outlines its role in dissecting mTORC1/mTORC2 signaling in preclinical models.

Protocol Parameters

• Assay: Biochemical mTOR kinase inhibition | Value: IC50 = 0.8 nM | Applicability: Use for in vitro enzyme assays or mechanistic cell studies | Rationale: Allows precise titration in kinase activity assays and cell proliferation studies | Source type: product information
• Assay: Compound solubility | Value: ≥23.3 mg/mL in DMSO; insoluble in water, ethanol | Applicability: Prepare stock solutions in DMSO and dilute into assay media as needed | Rationale: Ensures complete dissolution for reproducible dosing; prevents precipitation in aqueous systems | Source type: product information
• Assay: Storage conditions | Value: -20°C (solid form); avoid long-term storage of solutions | Applicability: Store dry powder at -20°C; prepare solutions fresh for each experiment | Rationale: Maintains compound integrity; minimizes degradation and loss of potency | Source type: product information
• Assay: Working concentrations (cell-based assays) | Value: Nanomolar range (typical: 10–100 nM) | Applicability: Titrate within this range for cancer cell proliferation and pathway inhibition studies | Rationale: Based on observed reduction of proliferation markers in breast cancer cell lines | Source type: product information
• Assay: Animal dosing (preclinical models) | Value: Intraperitoneal injection, dose as per experimental design | Applicability: Select dosing based on animal model and endpoint; consult original experimental methodology | Rationale: Supports evaluation of systemic effects, e.g., glucose metabolism and insulin levels | Source type: product information

Workflow Setup and QC Checklist

For reliable results when working with AZD8055, follow these best practices:

• Compound Handling: Upon receipt, store AZD8055 as a solid at -20°C. Minimize freeze-thaw cycles. If using APExBIO-sourced material, reference the manufacturer's guidelines for stability and handling.
• Stock Preparation: Dissolve compound in 100% DMSO to prepare concentrated stocks (≥23.3 mg/mL). Vortex thoroughly and inspect for complete dissolution. Filter sterilize if sterility is required.
• Aliquoting: Prepare single-use aliquots to avoid repeated freeze-thaw, which may compromise activity.
• Solution Use: Dilute DMSO stocks into cell culture medium or in vivo vehicle immediately before use. Do not store working solutions for extended periods; make fresh before each experiment.
• Concentration Verification: Confirm final DMSO concentration in working solutions does not exceed cytotoxic thresholds for the assay system. Typical final DMSO is ≤0.1% v/v for cell-based assays.
• Negative and Positive Controls: Include vehicle controls and, where possible, a known mTORC1/mTORC2 inhibitor for assay benchmarking.
• Pathway Validation: Verify mTOR pathway inhibition by monitoring downstream markers (e.g., phosphorylation status of S6K, AKT, or 4EBP1) via western blot or other quantitative assays.
• Documentation: Record lot numbers, preparation dates, and storage conditions for traceability.

For additional workflow context and troubleshooting, consult the internal resource "Technical Guidance for Using AZD8055 as an mTOR Inhibitor", which provides further details on experimental setup for mTOR pathway analysis in preclinical models.

Common Failure Modes and Fixes

• Precipitation in Aqueous Media: If AZD8055 precipitates after dilution, confirm the initial stock is fully dissolved in DMSO and that final DMSO concentration is sufficient to maintain solubility. Mix thoroughly before addition to media.
• Loss of Activity: Observed loss of mTOR pathway inhibition may indicate compound degradation. Always prepare fresh working solutions and avoid prolonged storage in solution form, even at -20°C.
• Variable Cellular Responses: Differences in sensitivity between cell lines can occur; titrate AZD8055 concentration within the nanomolar range and verify pathway inhibition by analyzing downstream effectors.
• Cytotoxicity from DMSO: High DMSO concentrations may cause nonspecific toxicity. Keep final DMSO below 0.1% v/v in cell-based experiments.
• Batch-to-Batch Variation: If encountering unexpected results, verify batch documentation and compare activity to previous lots.

Scope and Limitations

AZD8055 is validated for use in preclinical cancer and metabolic research models, enabling specific inhibition of both mTORC1 and mTORC2 complexes. Its high selectivity minimizes confounding off-target effects, making it ideal for mechanistic studies of the PI3K/Akt/mTOR signaling network. However, the compound is not suitable for studies where clinical efficacy is the primary research goal, as phase I trials have shown minimal benefit. It should not be used for projects requiring translation to clinical endpoints or for broad-spectrum kinase inhibition.

All protocol parameters and workflow recommendations are based on the product dossier and established best practices in kinase inhibitor handling. Where quantitative data is not provided in the product information, users should titrate experimentally to optimize for their system.

Conclusion

AZD8055 is a focused tool for selective, dual mTORC1/mTORC2 inhibition in preclinical research, supporting detailed mechanistic studies of cancer cell proliferation and metabolism. Adhering to recommended storage, solubility, and dosing protocols is essential for consistent results. For researchers seeking an mTOR signaling pathway inhibitor with high specificity for mechanistic studies, AZD8055 from APExBIO offers a robust solution. Refer to the AZD8055 product page for complete preparation and storage guidelines.